Log In
Print
BCIQ
Print
Print this Print this
 

samatasvir (IDX719)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionOnce daily HCV NS5A protein inhibitor
Molecular Target HCV NS5A protein
Mechanism of ActionHCV non-structural protein 5A inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1b or 4 infection in non-cirrhotic, treatment-naïve patients; Treat chronic HCV infection; Treat HCV infection
Regulatory Designation

U.S. - Fast Track (Treat chronic HCV infection)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today